The NIHR Translational Research Collaboration in joint and related inflammatory diseases (TRC) brings together internationally recognised investigators in the UK's leading centres of excellence to carry out early phase research.
This NIHR Translational Research Collaboration carries out outstanding translational research in joint and related inflammatory diseases.
Together with industry partners, the TRC focuses on early phase clinical research in patients to identify mechanisms of pathophysiology of disease, or to demonstrate proof of concept or evidence of the validity of new discoveries or treatments.
The TRC undertake commercial and non-commercial studies with industry partners, and engages with all sectors of the life sciences industry, including Clinical Research Organisations (CROs).
To be suitable for TRC support, a project is expected to:
The TRC experts will help you to shape your protocol, providing advice on study design. If you already have a fully-developed protocol and are only looking for recruitment sites the NIHR Clinical Research Network will be able to help you. Find out more about this service in the Support my study section of this website.
The TRC can offer scientific advice when there is a clear intent to deliver the study through the TRC, they are not designed to act as stand-alone advisory boards.
The TRC provide easy access to a network of academic centres and experts embedded in UK universities and NHS hospitals who are available to work collaboratively on early phase clinical studies.
The TRC centres operate to common business processes. This makes it quicker and easier for industry to work with the expert investigators within the NHS.
The TRC provide operational support, including a standard pre-approved non-disclosure agreement, contractual templates and a close working relationship with the NIHR Clinical Research Network for identification of sites.
The TRC specialties include:
The TRC regularly reviews areas of unmet clinical need to determine emerging topics that could become a focus for the group.
|Professor David Isenberg||University College London Hospitals NHS Foundation Trust; Royal Free London NHS Foundation Trust; University College London|
|Professor Peter C Taylor||Oxford University Hospitals NHS Trust; University of Oxford|
|Professor John Isaacs||The Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle University|
|Professor Costantino Pitzalis||Barts Health NHS Trust; Queen Mary University of London|
|Professor Ian Bruce||Manchester Academic Health Science Centre|
|Professor Chris Buckley||The University of Birmingham; Birmingham/Sandwell/Dudley Hospitals|
|Dr Natasha Jordan||Cambridge University Hospitals NHS Foundation Trust; University of Cambridge|
|Dr Matthew Pickering||Imperial College London; Imperial College Healthcare NHS Trust|
|Professor Andrew Cope||King's Health Partners Academic Health Science Centre|
|Professor David Walsh||Nottingham University Hospitals NHS Trust; University of Nottingham|
|Professor Maya Buch||University of Leeds; Leeds Teaching Hospitals NHS Trust|
|Professor Chris Edwards||University of Southampton; University Hospital Southampton NHS Foundation Trust|
A clinical trial to develop new treatments for patients with the chronic autoimmune disease systemic lupus erythematosus (SLE) is being run by the TRP in joint and related inflammatory diseases.
The biological drug Rituximab can provide temporary improvements for lupus patients and was approved as a treatment in 2012. However after the initial improvements, some patients can experience ever worsening flares. The research team believe that another drug, belimumab, could be used to prevent flares in patients with SLE post rituximab therapy by blocking the actions of the B cell growth factor BAFF.
A pioneering drug is being tested by the TRP in joint and related inflammatory diseases which could bring hope to the millions of Britons who are likely to one day suffer from arthritis. The drug aims to prevent people from developing arthritis, unlike existing treatments that only treat the debilitating disease once it has set in.
The study of the drug Abatacept is the world's largest ever trial investigating whether targeted immunotherapy can prevent rheumatoid arthritis in individuals considered to be at high risk of developing the disease.